Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
Authors
Keywords
-
Journal
Advanced Science
Volume -, Issue -, Pages 2003263
Publisher
Wiley
Online
2020-12-30
DOI
10.1002/advs.202003263
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
- (2019) Minjiang Chen et al. EBioMedicine
- Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer
- (2019) Zhongtai Wang et al. Cancer Medicine
- Genomic Signature of Driver Genes Identified by Target Next‐Generation Sequencing in Chinese Non‐Small Cell Lung Cancer
- (2019) Shiwang Wen et al. ONCOLOGIST
- Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
- (2019) Wenhua Liang et al. CANCER SCIENCE
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China
- (2019) Pu‐Yuan Xing et al. Cancer Medicine
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
- (2018) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients
- (2018) Jeong Uk Lim et al. International Journal of Chronic Obstructive Pulmonary Disease
- Minimal functional driver gene heterogeneity among untreated metastases
- (2018) Johannes G. Reiter et al. SCIENCE
- NetSig: network-based discovery from cancer genomes
- (2017) Heiko Horn et al. NATURE METHODS
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Targeted therapy for NSCLC with driver mutations
- (2013) Gabriele Minuti et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
- (2010) Matthew D. Wilkerson et al. BIOINFORMATICS
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started